Saghir Akhtar is professor of pharmacology in the College of Medicine, Qatar University,[1] and editor in chief of the Journal of Drug Targeting.
He led a team studying DNA chip technology with a hope of combatting a form of brain cancer known as glioma.
He later became professor of Drug Delivery in the Welsh School of Pharmacy and Director for the Centre for Genome-based Therapeutics, Cardiff University, UK (2002–2006).
More recently he was Professor of Pharmacology at Kuwait University Faculty of Medicine (2007-2017) where he also served as Director of the Graduate program.
[4] His current research interests include studying molecular pharmacology and signal transduction pathways involved in diabetes and/or hypertension-induced cardiovascular dysfunction, and understanding the biological and pharmaceutical challenges associated with the development of gene silencing nucleic acids (RNA interference/ siRNA/ antisense oligonucleotides) as potential therapeutic agents; and c) studying the toxicogenomics of novel drugs and non-viral drug delivery systems.